Monday, October 2, 2023
Monday, October 2, 2023

Contact: 561.316.3330

Robot Hip Surgeons: New Trial to Test Performance Against Humans

Robots will have their surgical skills put to the test as researchers trial their use in hip replacement surgery for the first time.

Pitting them against their human counterparts, the aim is to determine whether using robots results in better outcomes from hip replacement surgery. Hip replacement surgery is one of the most common operations performed by the NHS.

The world-first RACER-Hip Study has received £1 million in funding from the National Institute for Health and Care Research (NIHR) and, alongside the existing RACER-Knee study announced last year, will give new insight into the value of robotic-assisted surgery in the NHS. It will be run jointly between Warwick Medical School at the University of Warwick, University Hospitals Coventry and Warwickshire (UHCW) NHS Trust, and the Royal Orthopaedic Hospital (ROH) in Birmingham.

Robotic-assisted hip and knee replacement surgery have increased rapidly over the last three years, particularly in the USA. Robotic systems are being introduced into the NHS and presented to the public as innovative best practice. However, there is currently little evidence to show that these systems are better than conventional surgery.

In robotic-assisted hip replacement surgery, a robotic arm prepares the bone and inserts the components into a pre-programmed three-dimensional plan. It is thought using a robot to perform the surgery allows for more precise, consistent surgical techniques and this may help to reduce variation and prevent poor outcomes and complications that can require redo surgery.

The study is being led by two surgeons, Mr. Peter Wall, from the Royal Orthopaedic Hospital Birmingham and Warwick Clinical Trials Unit at the University of Warwick, and Professor Ed Davis, from the Royal Orthopaedic Hospital Birmingham.

Mr. Wall said: “The RACER-Hip study is a significant investment by the NHS to examine the effectiveness of robotic hip replacement surgery.”

“Robotic technology has the potential to revolutionize hip replacement surgery, however, the first step to this is understanding whether it can help enhance the care surgeons provide.”

“We are really excited that some centers such as Northumbria Healthcare NHS Foundation Trust have been provided with a robot specifically to take part in this research.”

Professor Davis added: “The research will help orthopedic surgeons across the world to better understand the most effective tools for performing hip replacement surgery and ensure the very best outcomes for their patients.

“This study will also include an in-depth health economic analysis to inform the NHS if this technology should be widely adopted.”

Equal numbers of participants will be randomized to each treatment group to find out which surgical technique results in better outcomes. This will include asking questions about people’s ability to complete activities and their quality of life in the long term and will also find out which method provides the best value for the NHS.

The team will invite patients from at least six NHS hospitals across England and Scotland to take part over the coming months. The first site has opened at the Royal Orthopaedic Hospital, while the Northumbria Healthcare NHS Foundation Trust has just taken delivery of one of the robots for the trial, the first time this service will be available within the NHS for hip operations in the Northeast of England. The manufacturer of the robot, Stryker, will be supporting the study costs to ensure hospitals do not have to pay extra to take part.

RACER-Hip joins the RACER-Knee study which began recruitment 12 months ago and is helping answer the same questions for knee replacement surgery. The RACER studies represent a substantial investment of over £3 million by the NHS to help establish the effectiveness of robotic joint replacement surgery. Leading professional bodies including the Royal College of Surgeons, British Hip Society, and British Association of Knee Surgery all recognize the importance of and support the research initiative which will see the UK lead the way in research in robotic joint replacement surgery.

Medical Device News Magazine
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

4SC Receives Orphan Drug Designation (ODD) for resminostat (Kinselby) in CTCL from the US FDA

Jason Loveridge, Ph.D., CEO of 4SC, commented: “Receiving orphan drug designation for resminostat provides us with a number of important benefits, most crucially 7 years’ market exclusivity in the US, a key foundation of our efforts to commercialise Kinselby.  We are currently preparing a marketing authorisation application for Kinselby in the EU, which remains on track for submission in Q1 2024.”

Abyrx Receives FDA Clearance for MONTAGE ® Settable Bone Putty for Use in Cardiothoracic Surgery

By expanding the range of FDA-cleared surgical applications for MONTAGE, this latest milestone positions Abyrx to build upon the more than 25,000 units of MONTAGE that have been used to date by surgeons in trauma, orthopedics, sports medicine, foot and ankle, and craniomaxillofacial procedures.

FDA Grants Fast Track Designation to 9MW3011

9MW3011 has been approved to clinical study by NMPA and FDA, respectively. The first person has been dosed in the clinical study in China in March, 2023.

MicuRx receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation for Contezolid and Contezolid acefosamil

"We are pleased to gain the QIDP and Fast Track designations for DFI as recognition that contezolid and contezolid acefosamil are novel new agents to meet an important unmet need in this common and challenging infection", stated Dr Zhengyu Yuan, Chief Executive Officer at MicuRx. 

Via Nova Therapeutics Announces FDA clearance of Investigational New Drug (IND) Application for VNT-101

"We look forward to evaluating VNT-101 in the clinic," said Don Ganem MD, Co-Founder and CEO of Via Nova Therapeutics. "This is an important step to developing a flu antiviral with a novel mechanism of action, and a milestone for Via Nova Therapeutics as we advance our first compound into the clinic."

By using this website you agree to accept Medical Device News Magazine Privacy Policy